Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | SVP, Commercial Operations | March 06, 2026 | March 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUPERNUS PHARMACEUTICALS, INC.
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-03-10 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-03-06 · Exercise / conversion · Acquired 2,625 · Balance 7,457 Row 2 · 2026-03-06 · Tax withholding · Disposed 1,216 · Balance 6,241 F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Row 3 · 2026-03-06 · Exercise / conversion · Acquired 3,750 · Balance 9,991 Row 4 · 2026-03-06 · Tax withholding · Disposed 1,718 · Balance 8,273 F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Row 5 · 2026-03-06 · Exercise / conversion · Acquired 1,125 · Balance 9,398 Row 6 · 2026-03-06 · Tax withholding · Disposed 521 · Balance 8,877 F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Row 7 · 2026-03-09 · Sale · Disposed 4,438 · Balance 4,439 Row 8 · 2026-03-10 · Sale · Disposed 4,439 · Balance 0 |
| Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-03-06 · Exercise / conversion · Disposed 2,625 · Balance 0 F2: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. |
| Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-03-06 · Exercise / conversion · Disposed 3,750 · Balance 0 F2: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. |
| Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-03-06 · Exercise / conversion · Disposed 1,125 · Balance 0 F2: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F2: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 4,439 | $55.00 | $244,145.00 |
DisclosureSEC source: 0002117599-26-000004 · wk-form4_1773173526.xml · nonDerivative · entry 8 Horich William Todd · CIK 0002117599 · SVP, Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| March 09, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 4,438 | $54.00 | $239,652.00 |
DisclosureSEC source: 0002117599-26-000004 · wk-form4_1773173526.xml · nonDerivative · entry 7 Horich William Todd · CIK 0002117599 · SVP, Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,439 Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 1,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002117599-26-000004 · wk-form4_1773173526.xml · derivative · entry 11 Horich William Todd · CIK 0002117599 · SVP, Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F2 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002117599-26-000004 · wk-form4_1773173526.xml · derivative · entry 10 Horich William Todd · CIK 0002117599 · SVP, Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F2 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 2,625 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002117599-26-000004 · wk-form4_1773173526.xml · derivative · entry 9 Horich William Todd · CIK 0002117599 · SVP, Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F2 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 521 | $54.73 | $28,514.33 |
DisclosureSEC source: 0002117599-26-000004 · wk-form4_1773173526.xml · nonDerivative · entry 6 Horich William Todd · CIK 0002117599 · SVP, Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,877 F1 · kind: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 1,125 | $0.00 | $0.00 |
DisclosureSEC source: 0002117599-26-000004 · wk-form4_1773173526.xml · nonDerivative · entry 5 Horich William Todd · CIK 0002117599 · SVP, Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 1,718 | $54.73 | $94,026.14 |
DisclosureSEC source: 0002117599-26-000004 · wk-form4_1773173526.xml · nonDerivative · entry 4 Horich William Todd · CIK 0002117599 · SVP, Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,273 F1 · kind: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0002117599-26-000004 · wk-form4_1773173526.xml · nonDerivative · entry 3 Horich William Todd · CIK 0002117599 · SVP, Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 1,216 | $54.73 | $66,551.68 |
DisclosureSEC source: 0002117599-26-000004 · wk-form4_1773173526.xml · nonDerivative · entry 2 Horich William Todd · CIK 0002117599 · SVP, Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,241 F1 · kind: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0002117599-26-000004 · wk-form4_1773173526.xml · nonDerivative · entry 1 Horich William Todd · CIK 0002117599 · SVP, Commercial Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.